ライフサイエンスコーパス: islet transplantation

1 for insulin independence after single-donor islet transplantation.

2 for patients with type 1 diabetes undergoing islet transplantation.

3 DSCs as a novel adjunctive immunotherapy for islet transplantation.

4 three patients immediately after intraportal islet transplantation.

5 ight, and fasting blood glucose levels after islet transplantation.

6 tolerance induction for clinical xenogeneic islet transplantation.

7 ch to successfully establishing subcutaneous islet transplantation.

8 hat GABA might find applications in clinical islet transplantation.

9 (de novo expression or titer increase) after islet transplantation.

10 Rs may be a useful adjunct therapy for human islet transplantation.

11 t rejection is one of the main obstacles for islet transplantation.

12 ulin-dependent) diabetes mellitus, including islet transplantation.

13 justify early clinical trials of IDN6556 in islet transplantation.

14 rategy is likely to improve outcome in human islet transplantation.

15 n of a macrochamber specially engineered for islet transplantation.

16 their depletion can thus be advantageous for islet transplantation.

17 ntly used immune suppression (IS) regimen in islet transplantation.

18 nd protein expression levels increased after islet transplantation.

19 fect of B-cell depletion in murine models of islet transplantation.

20 beneficial as an alternative to intrahepatic islet transplantation.

21 i-islet immune response in various models of islet transplantation.

22 ly aid in increasing the success of clinical islet transplantation.

23 in early islet graft loss after intraportal islet transplantation.

24 n vivo in allogenic and autoimmune models of islet transplantation.

25 ytotoxicity, but not splenic NK cells, after islet transplantation.

26 pendence in type 1 diabetic recipients after islet transplantation.

27 RL) has beneficial effects on beta cells for islet transplantation.

28 ation and beta-cell death by apoptosis after islet transplantation.

29 tation with islet grafts in a mouse model of islet transplantation.

30 ts instead of culturing for current clinical islet transplantation.

31 its potential use in the context of clinical islet transplantation.

32 ow use this purification method for clinical islet transplantation.

33 te (GFR) have been observed after successful islet transplantation.

34 unction with low dose tacrolimus, in current islet transplantation.

35 ur way to clinical use of in vivo imaging of islet transplantation.

36 iabetic monkeys received intraportal porcine islet transplantation.

37 great promise for large-scale application of islet transplantation.

38 lant candidate, preferentially allocated for islet transplantation.

39 e presence of endocrine non-beta-cells after islet transplantation.

40 erred with severe hypoglycemia, suitable for islet transplantation.

41 ts, including whole pancreas and kidney, and islet transplantation.

42 recurrence of autoimmune diabetes following islet transplantation.

43 development of donor-specific immunity after islet transplantation.

44 roach could be used clinically to facilitate islet transplantation.

45 ervention might improve outcomes after human islet transplantation.

46 Ten monkeys underwent intraportal porcine islet transplantation.

47 ognized, but scattered data is available for islet transplantation.

48 indicator of beta-cell secretory capacity in islet transplantation.

49 in mice with pre-existing disease following islet transplantation.

50 its importance in clinical settings such as islet transplantation.

51 -beta-cells are not essential for successful islet transplantation.

52 ophic approach may prove beneficial in human islet transplantation.

53 tes and glycemic control was monitored after islet transplantation.

54 viable islet mass after clinical intraportal islet transplantation.

55 is currently incompatible with intrahepatic islet transplantation.

56 lear cell co-cultured exosomes for improving islet transplantation.

57 tuate disease and are rapidly reactivated by islet transplantation.

58 lity, negatively affecting outcomes of human islet transplantation.

59 beta cell dysfunction in type 2 diabetes and islet transplantation.

60 unction, both of which hinder the success of islet transplantation.

61 tained normoglycemia for up to 60 days after islet transplantation.

62 tion of therapeutic interventions, including islet transplantation.

63 ft function still remains inconsistent after islet transplantation.

64 as a new approach to improve the outcomes of islet transplantation.

65 rapies, as adjuncts for immunosuppression in islet transplantation.

66 The Clinical Islet Transplantation 07 (CIT07) protocol uses antithymo

67 Before islet transplantation, 10 patients (59%) were screened p

68 s revealed US $57,525 of additional cost for islet transplantation 5 years after transplantation.

69 Clinical islet transplantation achieves insulin independence in s

70 Islet transplantation after successful kidney transplant

71 In the absence of islet transplantation, all diabetic mice remained diabet

72 istry reports have suggested that results of islet transplantation alone in this indication may be ab

73 Transplants in the IAK and islet transplantation alone setting demonstrated similar

74 in our program where nine patients underwent islet transplantation alone treated with Edmonton immuno

75 Kidney function remained stable after islet transplantation alone.

76 centrations were monitored for 30 days after islet transplantation and animals were then subjected to

77 with type 1 diabetes who received pancreatic islet transplantation and anti-CD25 mAb as induction the

78 use of rapamycin as an immunosuppressant in islet transplantation and as a second-line agent in othe

79 We characterize donor utilization for islet transplantation and estimate the number of recipie

80 This addresses a key challenge facing islet transplantation and importantly, the clinical appl

81 improving beta-cell survival following human islet transplantation and increasing beta-cells in patie

82 We investigated whether islet transplantation and insulin treatment can relieve

83 mulates specifically in the beta-cells after islet transplantation and is a promising tracer for noni

84 e results and could be performed both before islet transplantation and on preserved cell blocks at an

85 potential to improve graft survival in human islet transplantation and other cellular therapies on th

86 sulin production in both type 2 diabetes and islet transplantation and point to the potential for the

87 ed macaques underwent intraportal allogeneic islet transplantation and received basiliximab and sirol

88 at the adrenal may be an attractive site for islet transplantation and that GHRH analogs might allow

89 mycin could negatively impact the success of islet transplantation and the adaptation of beta-cells t

90 ediated attack is a substantial challenge in islet transplantation and this will extend to applicatio

91 nts who became insulin independent after one islet transplantation and those who did not.

92 Ig)-like transcript (ILT) 3-Fc in pancreatic islet transplantation and to determine its mechanism of

93 study aimed to evaluate long-term effects of islet transplantation and to outline possible influentia

94 ed insulin independence after a single-donor islet transplantation, and 149 did not.

95 ul tools for studying beta-cell development, islet transplantation, and beta-cell autoimmunity.

96 moglycemia in diabetic mice after pancreatic islet transplantation, and results in reduced tumor volu

97 Whole pancreas and islet transplantation are currently used for the treatme

98 eversal of liver ischemia due to intraportal islet transplantation are detectable using T2-weighted M

99 Recent advances in human islet transplantation are hampered by significant graft

100 DSA or autoantibody increases after islet transplantation are important prognostic markers,

101 Both pancreas and islet transplantations are therapeutic options for compl

102 In this study, we used allogeneic islet transplantation as a model indication to assess th

103 aft survival limits the long-term success of islet transplantation as a potential curative therapy fo

104 ls significantly increased after intraportal islet transplantation as compared with the control.

105 The applicability of islet transplantation as treatment for type 1 diabetes i

106 from patients with autologous and allogeneic islet transplantation as well as total pancreatectomy al

107 Subjects undergoing islet transplantation at a single center (Edmonton, Cana

108 of graft survival in the stringent model of islet transplantation (BALB/c into NOD).

109 biomarker to detect graft damage in clinical islet transplantation because serum C-peptide and proins

110 As islet transplantation becomes an acceptable clinical mod

111 As islet transplantation begins to show promise as a clinic

112 Thus, they may improve islet transplantation by delivering small RNAs for promo

113 roves islet graft survival after intraportal islet transplantation by mitigation of coagulation in IB

114 e results provide evidence that intrahepatic islet transplantation can restore glucose counterregulat

115 Islet transplantation can restore normoglycemia to patie

116 Islet transplantation can temporarily cure type 1 diabet

117 onal Institutes of Health-sponsored Clinical Islet Transplantation (CIT) Consortium jointly developed

118 Whilst islet transplantation combined with immune suppression h

119 Islet transplantation consisted of three sequential fres

120 Outcomes after islet transplantation continue to improve but etiology o

121 bjects with severe hypoglycemia suitable for islet transplantation, CSII decreased hypoglycemia frequ

122 ontinued success of whole organ pancreas and islet transplantation, deceased donor pancreas allocatio

123 Long-term insulin independence after islet transplantation depends on engraftment of a large

124 Successful islet transplantation depends on the infusion of suffici

125 Improved immunosuppressive regimens in islet transplantation developed in the Edmonton protocol

126 Subcutaneous tissue is a promising site for islet transplantation, due to its large area and accessi

127 In conclusion, intrahepatic islet transplantation effectively restores the liver to

128 is the current site of choice for pancreatic islet transplantation, even though it is far from being

129 ntly depleted B cells in all three models of islet transplantation examined.

130 Pancreatic resection with autologous islet transplantation for severe chronic pancreatitis is

131 ucted in 35 subjects submitted to pancreatic islet transplantation for treatment of unstable type 1 d

132 Problems associated with islet transplantation for Type 1 Diabetes (T1D) such as

133 Islet transplantation for type 1 diabetes can enable the

134 cantly improving the therapeutic efficacy of islet transplantation for type 1 diabetes.

135 Thus, allogeneic islet transplantation had a positive systemic effect in

136 Because islet transplantation has become a promising treatment o

137 Clinical islet transplantation has become an established treatmen

138 Islet transplantation has been explored, but it does not

139 , semi-allogeneic splenocytes, and temporary islet transplantation has been reported to cure NOD mice

140 Islet transplantation has been reported to induce allose

141 his article, we address the question whether islet transplantation has indeed bridged the gap with wh

142 The impact of IA on islet transplantation has never been explored.

143 migration, their influence on the outcome of islet transplantation has not been characterized.

144 Islet transplantation has proven to be a successful stra

145 Pancreatic islet transplantation has recently emerged as a powerful

146 Islet transplantation has recently emerged as an accepta

147 Pancreatic islet transplantation has shown great success in the tre

148 Pancreatic islet transplantation has the potential to cure type 1 d

149 omposite measure of beta cell function after islet transplantation, has limited sensitivity because o

150 Until recent years, outcomes of islet transplantation have been significantly inferior t

151 After islet transplantation, HbA1c was normalized, and time sp

152 After islet transplantation, IA-positive patients achieved ins

153 ents who could achieve normoglycemia through islet transplantation if the current donor pool were use

154 study was to determine whether intrahepatic islet transplantation improves endogenous glucose produc

155 iver and islet engraftment after intraportal islet transplantation in a clinical setting.

156 e report that the efficiency of subcutaneous islet transplantation in a Lewis rat model is significan

157 nvestigate tolerance induction protocols for islet transplantation in a setting of autoimmunity.

158 pididymal fat pad was evaluated as a site of islet transplantation in a syngeneic murine model of dia

159 ent of glycemic control following pancreatic islet transplantation in animal models is discussed.

160 We showed that islet transplantation in confined well-vascularized site

161 t feasibility and safety of BM as a site for islet transplantation in humans.

162 nd monitors comprehensive data on allogeneic islet transplantation in North America, Europe, and Aust

163 the metabolic outcomes and graft survival of islet transplantation in our program where nine patients

164 Previous studies have shown that islet transplantation in the testis significantly prolon

165 lity is an obstacle to the widespread use of islet transplantation in type 1 diabetic patients.

166 ctiveness of an intervention, especially for islet transplantation in which benefits should outweigh

167 In-depth analysis reveals that islet transplantation, in fact, has an edge on whole pan

168 autoimmune setting, such as with pancreas or islet transplantation into a type 1 diabetic individual,

169 nhibited human beta-cell apoptosis following islet transplantation into NOD/scid mice.

170 glycemia, we developed a model of pancreatic islet transplantation into the liver.

171 Islet transplantation into the scaffold resulted in norm

172 -producing beta cells in type 1 diabetes and islet transplantation involves a variety of immune pathw

173 Although human islet transplantation is a cell-based therapy under clin

174 Islet transplantation is a feasible therapeutic alternat

175 Islet transplantation is a poorly investigated long-term

176 beta-Cell replacement by islet transplantation is a potential curative therapy fo

177 Islet transplantation is a potential treatment for type

178 Pancreatic islet transplantation is a promising clinical treatment

179 Pancreatic islet transplantation is a promising potential cure for

180 Islet transplantation is a promising therapeutic approac

181 Islet transplantation is a promising treatment for type

182 pancreatic beta-cells through deceased donor islet transplantation is a proven therapy for preventing

183 Islet transplantation is a recognized treatment option f

184 Islet transplantation is a successful beta-cell replacem

185 Islet transplantation is a successful beta-cell replacem

186 reatment of patients with type 1 diabetes by islet transplantation is affected by a multitude of fact

187 Islet transplantation is an alternative to pancreas tran

188 Islet transplantation is an effective method to obtain l

189 Islet transplantation is an effective therapy in type 1

190 Autologous islet transplantation is an elegant and effective method

191 Islet transplantation is an established therapy for diab

192 Intrahepatic islet transplantation is an experimental therapy for typ

193 Allogeneic islet transplantation is an important therapeutic approa

194 Islet transplantation is associated with long-term impro

195 rease of MMP-9 expression and activity after islet transplantation is directly related to enhanced le

196 Islet transplantation is emerging as a treatment option

197 Cost analysis revealed that islet transplantation is estimated to be cost neutral at

198 Long-term clinical outcome of islet transplantation is hampered by the rejection and r

199 The success of pancreatic islet transplantation is limited because of immune rejec

200 Islet transplantation is limited by the need for chronic

201 e compounded by the induction of diabetes if islet transplantation is planned.

202 nsulin resistance, and their avoidance after islet transplantation is preferred from a metabolic stan

203 Islet transplantation is primarily performed alone in pa

204 A current limitation of islet transplantation is reduced long-term graft functio

205 A major challenge for human allogeneic islet transplantation is the development of effective me

206 A significant barrier to islet transplantation is the rapid loss of human islet f

207 For pancreatic islet transplantation, islet purification minimizes the

208 l state of type-1 diabetes as well as during islet transplantation.Islet transplantation is considere

209 onal status and behavior are associated with islet transplantation (ITx) and to assess their possible

210 , synergistically enhance angiogenesis after islet transplantation leading to stable engraftment.

211 ment in humans is safe, its use during human islet transplantation may be considered.

212 oidance of steroids; however, the outcome of islet transplantation may differ in kidney transplant re

213 with insulin independence after single-donor islet transplantation may help to select recipient-donor

214 Pancreatic islet transplantation may provide an effective therapy f

215 tched, nonlymphopenic, immunocompetent mouse islet transplantation model, alloTregs but not nTregs pr

216 reventing allograft rejection using a murine islet transplantation model.

217 ned and may best be addressed using a unique islet-transplantation model.

218 Using allogeneic islet transplantation models as well as NOD mice with re

219 In intraportal islet transplantation models using mouse and human islet

220 in vivo on INS-1 tumor (GLP-1R positive) and islet transplantation models.

221 slets at 4 degrees C improves the outcome of islet transplantation more efficiently than preservation

222 Clinical islet transplantation needs to be evaluated using the mo

223 Because of the lack of tissue available for islet transplantation, new sources of beta-cells have be

224 ce and 100% indefinite survival of syngeneic islet transplantation (NOD.SCID into NOD mice).

225 Islet transplantation normalized glycemia and increased

226 Cell replacement therapy and islet transplantation offer hope, especially for severel

227 Islet transplantation offers a potential therapy to rest

228 Pancreatic islet transplantation offers a promising biotherapy for

229 Human pancreatic islet transplantation offers diabetic patients tight glu

230 ry confirm the inarguably positive impact of islet transplantation on metabolic control in T1 diabete

231 tion of the autoimmune recurrence of T1DM in islet transplantation or endogenous islets.

232 d more obese donors were used more often for islet transplantation or research.

233 ing SI_INS mRNA and SI_16h insulin predicted islet transplantation outcome in nonobese diabetic (NOD)

234 nors (H-2(d)) to assess alloimmunization and islet transplantation outcomes in Akita recipients.

235 trategies will be of assistance in improving islet transplantation outcomes.

236 re and may be a useful strategy in improving islet transplantation outcomes.

237 lted in significant delay of rejection after islet transplantation (P<0.01 vs. control).

238 al tools to follow patients after pancreatic islet transplantation (PIT).

239 The efficacy of pancreatic islet transplantation (PITx) is reduced due to islet dam

240 cision-making before entering an intraportal islet transplantation protocol.

241 rategy to improve the efficiency of clinical islet transplantation protocols.

242 Islet transplantation provides a "cure" for type 1 diabe

243 In type I diabetes mellitus, islet transplantation provides a moment-to-moment fine r

244 Islet transplantation provides a promising approach for

245 Islet transplantation provides an approach to compensate

246 type 1 diabetic recipients after intraportal islet transplantation raises a question about the suitab

247 Fourteen islet transplantation recipients with long-term history

248 primary efficacy and the safety outcomes of islet transplantation reported to the NIDDK and JDRF fun

249 Islet transplantation represents a feasible therapeutic

250 ycemic variability compared with MDI whereas islet transplantation resolved hypoglycemia and further

251 intained for many years following successful islet transplantation, restoration of normal functional

252 However, in both groups, islet transplantation restored good glycemic control and

253 Our aim was to evaluate islet transplantation results at 1 year according to the

254 adverse events in Trials of Adult Pancreatic Islet Transplantation." RESULTS: There were no deaths or

255 cemia alone, coadministration of leptin with islet transplantation robustly improved control of gluco

256 duces an antibody-mediated rejection in this islet transplantation rodent model.

257 ortal system may not be the optimal site for islet transplantation, several extrahepatic sites have b

258 ng during radiologic or surgical intraportal islet transplantation significantly impair primary graft

259 s a suitable polymer to create an artificial islet transplantation site under the skin and supports i

260 mation, which has important ramifications to islet transplantation studies.

261 Islet transplantation success depends on the number and

262 therapeutic treatments for diabetes such as islet transplantation techniques.

263 Muscle is a promising alternative site for islet transplantation that facilitates rapid restoration

264 is preclinical in vivo large animal model of islet transplantation, the effect of triple-drug immunos

265 ro and in vivo in syngeneic murine models of islet transplantation, the function of conformally coate

266 ld be beneficial to improve the outcomes for islet transplantation therapy.

267 may underlie beta cell failure and/or hamper islet transplantation therapy.

268 aulic permeability and immune-protection for islet transplantation therapy.

269 In allogeneic model of islet transplantation, there was an initial islet loss a

270 reated 4 weeks before diabetes induction and islet transplantation through the transient placement of

271 s are lost in the early phase after clinical islet transplantation, through apoptosis, necrosis, or i

272 r immunosuppression limit the indication for islet transplantation to a small group of patients.

273 sirolimus+tacrolimus regimen 6 months before islet transplantation to exclude negative effects on kid

274 ous subcutaneous insulin infusion (CSII) and islet transplantation to reduce hypoglycemia and glycemi

275 insulin synthesis in islets is important for islet transplantation to succeed.

276 Islet transplantation to treat type 1 diabetes has been

277 immunity were performed antemortem after her islet transplantations to test in vitro for evidence of

278 bolic effects of diabetes were eliminated by islet transplantation (transplanted knockout (TKO)).

279 tion may lead to an alternative approach for islet transplantation treatment for diabetic patients.

280 active model for insulin supplementation and islet transplantation trials, and for studying developme

281 Immunosuppression (IS) in islet transplantation (Tx) is a double-edged sword: it p

282 Islet transplantation under the kidney capsule served as

283 ments for tolerance induction for xenogeneic islet transplantation using donor ECDI-SPs.

284 ation before and 6 months after intrahepatic islet transplantation using stepped hyperinsulinemic-hyp

285 169 human isolations processed for clinical islet transplantation, using five different lots of Libe

286 Reversal of hyperglycemia by islet transplantation was most successful in recipients

287 Rodent allogeneic islet transplantation was performed from DA rats to Lewi

288 Islet transplantation was performed in hyperglycemic B-c

289 Using polymer scaffolds as a platform for islet transplantation, we investigated the hypothesis th

290 h T1D and end-stage renal failure undergoing islet transplantation were compared to 70 patients match

291 Islet transplantations were performed in partially pancr

292 ents reached normoglycemia after intraportal islet transplantation when they were treated with AAT co

293 unstable type 1 diabetes mellitus underwent islet transplantation with alemtuzumab induction and sir

294 Islet transplantation with alemtuzumab induction was wel

295 Isolated islet transplantation with infusions from two to three d

296 study, using a murine model of subcutaneous islet transplantation with matrigel basement membrane ma

297 development of more effective strategies for islet transplantation without immunosuppression.

298 le investigational agent for use in clinical islet transplantation without relying upon CD154 blockad

299 lopment of a novel strategy for pig-to-human islet transplantation without side effects of systemic i

300 ta-cells, in volumes similar to that used in islet transplantation, would suffice to reverse hypergly